Security key
00461U105
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS)
CUSIP: 00461U105
Q3 2022 13F Holders as of 30 Sep 2022
- Type / Class
- Equity / Common Stock, $0.00001 par value
- Shares outstanding
- 138,752,791
- Total 13F shares
- 63,675,444
- Share change
- +345,628
- Total reported value
- $1,002,225,041
- Price per share
- $15.74
- Number of holders
- 124
- Value change
- +$5,530,098
- Number of buys
- 65
- Number of sells
- 32
Report period
Q3 2022
Institutions
124
Top holders
10
ACRS full security history
Newer quarter: Q4 2022
Previous quarter: Q2 2022
Aclaris Therapeutics, Inc. SEC filings
Aclaris Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 00461U105
Recent filing periods:
Top shareholders of ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
3.5%
|
4,901,263
|
$68,422,000 | — | 30 Jun 2022 | |
| BlackRock Finance, Inc. |
13F
|
Company |
3.4%
|
4,669,916
|
$65,191,000 | — | 30 Jun 2022 | |
| Venrock Adviser, LLC |
13F
|
Company |
3.3%
|
4,563,962
|
$63,713,000 | — | 30 Jun 2022 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
3.2%
|
4,398,453
|
$61,403,000 | — | 30 Jun 2022 | |
| BVF INC/IL |
13F
|
Company |
2.9%
|
3,976,543
|
$55,513,000 | — | 30 Jun 2022 | |
| Rock Springs Capital Management LP |
13F
|
Company |
2.8%
|
3,927,149
|
$54,823,000 | — | 30 Jun 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
2%
|
2,813,685
|
$39,279,000 | — | 30 Jun 2022 | |
| Foresite Capital Management IV, LLC |
13F
|
Company |
2%
|
2,808,034
|
$39,200,000 | — | 30 Jun 2022 | |
| Commodore Capital LP |
13F
|
Company |
1.7%
|
2,410,622
|
$33,652,000 | — | 30 Jun 2022 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
1.7%
|
2,325,500
|
$32,464,000 | — | 30 Jun 2022 | |
| Holocene Advisors, LP |
13F
|
Company |
1.5%
|
2,060,918
|
$28,770,000 | — | 30 Jun 2022 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.2%
|
1,733,900
|
$24,205,000 | — | 30 Jun 2022 | |
| Laurion Capital Management LP |
13F
|
Company |
1%
|
1,440,075
|
$20,103,000 | — | 30 Jun 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.96%
|
1,329,678
|
$18,562,000 | — | 30 Jun 2022 | |
| Foresite Capital Management V, LLC |
13F
|
Company |
0.91%
|
1,258,243
|
$17,565,000 | — | 30 Jun 2022 | |
| FMR LLC |
13F
|
Company |
0.9%
|
1,242,308
|
$17,343,000 | — | 30 Jun 2022 | |
| STATE STREET CORP |
13F
|
Company |
0.89%
|
1,230,241
|
$17,174,000 | — | 30 Jun 2022 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.85%
|
1,174,701
|
$16,399,000 | — | 30 Jun 2022 | |
| TCG Crossover Management, LLC |
13F
|
Company |
0.83%
|
1,144,939
|
$15,983,000 | — | 30 Jun 2022 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
0.78%
|
1,083,000
|
$15,119,000 | — | 30 Jun 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.69%
|
957,216
|
$13,362,000 | — | 30 Jun 2022 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.69%
|
953,072
|
$13,305,000 | — | 30 Jun 2022 | |
| Vivo Capital, LLC |
13F
|
Company |
0.65%
|
898,631
|
$12,545,000 | — | 30 Jun 2022 | |
| Samsara BioCapital, LLC |
13F
|
Company |
0.5%
|
696,171
|
$9,719,000 | — | 30 Jun 2022 | |
| Aisling Capital Management LP |
13F
|
Company |
0.46%
|
634,455
|
$8,857,000 | — | 30 Jun 2022 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.45%
|
625,000
|
$8,725,000 | — | 30 Jun 2022 | |
| Woodline Partners LP |
13F
|
Company |
0.45%
|
621,557
|
$8,677,000 | — | 30 Jun 2022 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.39%
|
539,545
|
$7,532,000 | — | 30 Jun 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.38%
|
523,679
|
$7,310,000 | — | 30 Jun 2022 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.33%
|
461,596
|
$6,444,000 | — | 30 Jun 2022 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.31%
|
436,260
|
$6,090,000 | — | 30 Jun 2022 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.29%
|
408,329
|
$5,700,000 | — | 30 Jun 2022 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.29%
|
407,889
|
$5,694,000 | — | 30 Jun 2022 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.25%
|
341,239
|
$4,764,000 | — | 30 Jun 2022 | |
| Verition Fund Management LLC |
13F
|
Company |
0.24%
|
334,666
|
$4,672,000 | — | 30 Jun 2022 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.22%
|
304,843
|
$4,256,000 | — | 30 Jun 2022 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.21%
|
293,045
|
$4,091,000 | — | 30 Jun 2022 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
0.21%
|
285,971
|
$3,992,000 | — | 30 Jun 2022 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.18%
|
250,714
|
$3,500,000 | — | 30 Jun 2022 | |
| HighVista Strategies LLC |
13F
|
Company |
0.16%
|
217,528
|
$3,037,000 | — | 30 Jun 2022 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.15%
|
202,169
|
$2,822,000 | — | 30 Jun 2022 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.14%
|
198,794
|
$2,775,000 | — | 30 Jun 2022 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.14%
|
192,835
|
$2,692,000 | — | 30 Jun 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0.12%
|
161,096
|
$2,249,000 | — | 30 Jun 2022 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.11%
|
154,319
|
$2,155,000 | — | 30 Jun 2022 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.08%
|
113,426
|
$1,583,000 | — | 30 Jun 2022 | |
| Swiss National Bank |
13F
|
Company |
0.07%
|
101,000
|
$1,410,000 | — | 30 Jun 2022 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.07%
|
100,000
|
$1,396,000 | — | 30 Jun 2022 | |
| Allianz Asset Management GmbH |
13F
|
Company |
0.07%
|
99,830
|
$1,394,000 | — | 30 Jun 2022 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.07%
|
96,694
|
$1,350,000 | — | 30 Jun 2022 |
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q3 2022
As of 30 Sep 2022,
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) was held by
124 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
63,675,444 shares.
The largest 10 holders included
BlackRock Inc., VR Adviser, LLC, RA CAPITAL MANAGEMENT, L.P., BVF INC/IL, Rock Springs Capital Management LP, WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, Foresite Capital Management IV, LLC, ORBIMED ADVISORS LLC, and COMMODORE CAPITAL LP.
This page lists
124
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2022 vs Q2 2022 Across Filers
Q2 2022 holders
112
Q3 2022 holders
124
Holder diff
12
| Investor | Q2 2022 Shares | Q3 2022 Shares | Share Diff | Share Chg % | Q2 2022 Value $ | Q3 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.